Natera Announces Q-Sub Filing with FDA for its Panorama® NIPT
Natera, Inc. (NASDAQ: NTRA) announced a pre-submission to the FDA for its Panorama® non-invasive prenatal test (NIPT) at the Canaccord Genuity 42nd Annual Growth Conference. This pre-submission, filed in June 2022, addresses fetal chromosomal aneuploidies and 22q11.2 deletion syndrome. The company cited its proactive collaboration with the FDA, supported by results from the SNP-based Microdeletion and Aneuploidy Registry Trial (SMART), the largest NIPT study with over 20,000 patients. Panorama screens for severe genetic disorders as early as nine weeks into pregnancy.
- Filed a pre-submission with the FDA for its Panorama test, indicating proactive regulatory engagement.
- SMART study enrollment exceeded 20,000 patients, demonstrating significant clinical validation.
- Panorama has a considerable body of evidence supporting its performance, including 26 peer-reviewed publications.
- The Panorama test has not yet been cleared or approved by the FDA, indicating ongoing regulatory uncertainty.
AUSTIN, Texas, Aug. 10, 2022 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, announced earlier today at the Canaccord Genuity 42nd Annual Growth Conference in Boston that the company has proactively filed a pre-submission to the FDA for its Panorama® non-invasive prenatal test (NIPT) as part of the Q-Sub process. The company filed its pre-submission in June 2022 for fetal chromosomal aneuploidies and for 22q11.2 deletion syndrome.
"NIPT has become the standard of care for prenatal screening," said Steve Chapman, CEO of Natera. "We have a track record of proactively engaging with the FDA and believe there are benefits to working with the Agency on this technology."
The pre-submission to the FDA follows the publication of results earlier this year from the SNP-based Microdeletion and Aneuploidy Registry Trial (SMART), the largest prospective NIPT study with confirmation of genetic outcomes, with more than 20,000 patients enrolled at 21 global medical centers. In addition to SMART, Natera has a significant body of evidence supporting the performance of its Panorama test, including 26 peer-reviewed papers, studying over 1.3 million patients.
About Panorama
Panorama screens for severe genetic disorders as early as nine weeks into pregnancy. The test uses a unique single-nucleotide polymorphism (SNP)-based technology to analyze fetal/placental DNA obtained through a blood draw from the mother. It is the only commercially available test that differentiates between maternal and fetal DNA to assess the risk of aneuploidies. Natera has published 26 papers, studying over 1.3 million patients, since the launch of Panorama. Panorama has been developed and its performance characteristics determined by Natera, the CLIA-certified laboratory performing the test. The test has not been cleared or approved by the US Food and Drug Administration (FDA). CAP accredited, ISO 13485 certified, and CLIA certified.
About Natera
Natera™ is a global leader in cell-free DNA testing, dedicated to oncology, women's health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard of care to protect health and enable earlier, more targeted interventions that help lead to longer, healthier lives. Natera's tests are validated by more than 100 peer-reviewed publications that demonstrate high accuracy. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas and San Carlos, California. For more information, visit www.natera.com.
Forward-Looking Statements
All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera's plans, estimates, or expectations will be achieved. These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including with respect to whether the results of clinical or other studies will support the use of our product offerings, the impact of results of such studies, or our expectations of the benefits of our tests and product offerings to patients, providers and payers. Additional risks and uncertainties are discussed in greater detail in "Risk Factors" in Natera's recent filings on Forms 10-K and 10-Q and in other filings Natera makes with the SEC from time to time. These documents are available at www.natera.com/investors and www.sec.gov.
Contacts
Investor Relations: Mike Brophy, CFO, Natera, Inc., 510-826-2350
Media: Brian Symmons, SVP of Marketing and Corporate Affairs, Natera, Inc., pr@natera.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/natera-announces-q-sub-filing-with-fda-for-its-panorama-nipt-301603792.html
SOURCE Natera, Inc.
FAQ
What was Natera's recent announcement regarding its Panorama test?
What does the Panorama test screen for?
How many patients were involved in the SMART study related to the Panorama test?
Has the Panorama test been approved by the FDA?
What technology does the Panorama test use?
